Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hyphens Pharma InternationalSGX:1J5 -2.70%82 Interest Coverage is 42.69 as of Jun. 2026, which is 19% below its 10-year median of 52.39. GuruFocus rates SGX:1J5 with a GF Score™ of 82/100 and a GF Value™ of S$0.31 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 94 Medical Distribution companies, Hyphens Pharma International ranks better than 78.72% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Hyphens Pharma International's
Operating Income
for the
six
months ended in Jun. 2026 was S$7.7 Mil. Hyphens Pharma International's Interest Expense for the
six
months ended in Jun. 2026 was S$-0.2 Mil.
Hyphens Pharma International's interest coverage for the quarter that ended in Jun. 2026 was 42.69.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Hyphens Pharma International's Interest Coverage or its related term are showing as below:
SGX:1J5'
s Interest Coverage Range Over the Past 10 Years
Min: 21.47 Med: 52.39 Max: 89.27
Current: 39.6
SGX:1J5's Interest Coverage is ranked better than 78.72% of 94
companies
in the Medical Distribution industry
Industry Median: 7.045
vs SGX:1J5: 39.60
Hyphens Pharma International (SGX:1J5) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Hyphens Pharma International Interest Coverage Related Terms
Hyphens Pharma International Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Hyphens Pharma International Interest Coverage Chart
SGX:1J5 vs MCK, COR, CAH: Interest Coverage Comparison
For the Medical Distribution subindustry, Hyphens Pharma International's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyphens Pharma International Interest Coverage vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Hyphens Pharma International's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Hyphens Pharma International's Interest Coverage falls into.
Hyphens Pharma International Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyphens Pharma International (SGX:1J5) has a Interest Coverage of 42.69 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Hyphens Pharma International and its competitors. This is 19% below median its historical median of 52.39. Over the past decade, Hyphens Pharma International's Interest Coverage has ranged from 21.47 to 89.27. According to the industry distribution chart, Hyphens Pharma International ranks #20 out of 94 companies in the Medical Distribution industry, placing it in the top 21.3%.
Is Hyphens Pharma International's Interest Coverage too high?
Hyphens Pharma International's current Interest Coverage of 42.69 is 19% below median its 10-year median of 52.39. Over the past 10 years, this metric has ranged from a low of 21.47 to a high of 89.27. The Medical Distribution industry median Interest Coverage is 7.05. Hyphens Pharma International's value of 42.69 is 506% above this industry median. Based on the distribution chart, Hyphens Pharma International ranks #20 out of 94 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Hyphens Pharma International has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hyphens Pharma International's Interest Coverage compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Hyphens Pharma International ranks #20 out of 94 companies for Interest Coverage. This places Hyphens Pharma International in the top 21% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 7.05. Hyphens Pharma International's value of 42.69 is 506% above this benchmark. Historically, Hyphens Pharma International's own Interest Coverage has ranged from 21.47 to 89.27 over the past decade. While the company's 10-year median is 52.39 vs. the industry median of 7.05, Hyphens Pharma International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Distribution company?
The median Interest Coverage among Medical Distribution companies is 7.05, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyphens Pharma International's current Interest Coverage of 42.69 is 506% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Hyphens Pharma International and its competitors. For the Medical Distribution industry, the median Interest Coverage is 7.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyphens Pharma International's current Interest Coverage is 42.69, which is 19% below median its own 10-year median of 52.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyphens Pharma International stock overvalued right now?
Based on GuruFocus' analysis, Hyphens Pharma International (SGX:1J5) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.31, compared to a current price of S$0.36 — trading 16.1% above its estimated fair value. The current Interest Coverage is 42.69, which is 19% below median its 10-year median of 52.39 and 506% above the Medical Distribution industry median of 7.05. Hyphens Pharma International's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Hyphens Pharma International (SGX:1J5), the current Interest Coverage is 42.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyphens Pharma International (SGX:1J5) Overvalued in 2026?
Based on GuruFocus' analysis, Hyphens Pharma International stock appears to be overvalued.
The current stock price of S$0.36 is trading 16.1% above its estimated GF Value™ of S$0.31.
GuruFocus considers Hyphens Pharma International to be Modestly Overvalued.
Key valuation signals for SGX:1J5:
Interest Coverage: 42.69 (19% below median its 10-year median of 52.39)
GF Value™: S$0.31 vs. price of S$0.36 (16.1% above fair value)
Industry Position: 506% above the Medical Distribution median (#20 of 94)
No single metric tells the full story. See the SGX:1J5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyphens Pharma International Ltd is a pharmaceutical company. Its segments include the Pharmaceutical and Medical Aesthetics segment; Proprietary Brands segment; and Digital Platform and E-Pharmacy segment. The Pharmaceutical and Medical Aesthetics segment engages in the business of marketing and selling a range of pharmaceutical and medical aesthetics products with exclusivity in the relevant ASEAN countries. The Proprietary Brands segment develops, markets, and sells dermatological, pharmaceuticals and health supplement products. The Digital Platform and E-Pharmacy segment is a digital platform servicing procurement needs of healthcare professionals, healthcare institutions, and retail pharmacies, mainly in Singapore.
82GF Score
Get the complete analysis for SGX:1J5
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:1J5 has been successfully added to your 
